← Trials/Trial dossier/NCT02462161

SNIFF-Quick

CompletedPhase 1

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

Lead sponsor

Wake Forest University Health Sciences

Asset

Insulin aspart

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•ADAS-Cog

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Nih5P50AG005136-30

Org study IDIRB00026106

NCT IDNCT02462161

Timeline

Milestones

Study start2015-03-20actual

Study first posted2015-06-03estimated

Primary completion2019-04-16actual

Study completion2019-04-16actual

Last update posted2025-07-28actual

Assets

Drug assets

Insulin aspart

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age50 Years

Maximum age89 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Previous or subsequent diagnosis of Alzheimer's disease or mild cognitive impairment

•Ability to communicate in English

Exclusion criteria

•Preexisting diabetes

•Clinically significant elevations in liver function test

•Clinically significant elevations in lipid profile

•Prior lumbar lumbar surgeries or other medical conditions that render lumbar punctures unsafe

•Hemoglobin <8 g/dl

•Significant neurologic disease that might affect cognition, other than Alzheimer's disease, including stroke, Parkinson's disease, multiple sclerosis, or recent severe head injury (within the last year) with loss of consciousness >30 minutes or with permanent neurologic sequelae

•Significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease

•Current use of antipsychotic, anticonvulsant, anxiolytic, anticoagulant or sedative medications

•Current or previous use of glucose-lowering agents or insulin;

•Chronic use (≥ 3 times per week) of nasal sprays of any type for any indication

•Premenopausal status (defined as having had a period within the last year).

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Amyloid biomarkers

Neuroimaging

Global cognition

1 endpoint

Primary/protocol endpoint

Change in cognition

Time frame:6 weeks and 12 weeks

ADAS-Cog

change from baseline, improvement

Amyloid biomarkers

1 endpoint

Secondary/protocol endpoint

Cerebral spinal fluid (CSF) and blood amyloid-beta, tau protein, and inflammatory markers

Time frame:Blood - every 6 weeks for 12 weeks; cerebral spinal fluid (CSF) - baseline and week 12

descriptive

Neuroimaging

1 endpoint

Secondary/protocol endpoint

MRI measure of cortical thickness in Alzheimer's disease (AD) -vulnerable regions

Time frame:Baseline and week 12

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.